Cellectis S.A. (ALCLS.PA)
- Previous Close
1.3380 - Open
1.3400 - Bid --
- Ask --
- Day's Range
1.3120 - 1.3560 - 52 Week Range
1.0120 - 2.6300 - Volume
56,513 - Avg. Volume
173,950 - Market Cap (intraday)
135.192M - Beta (5Y Monthly) 3.28
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5900 - Earnings Date Aug 4, 2025 - Aug 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.50
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
www.cellectis.comRecent News: ALCLS.PA
View MorePerformance Overview: ALCLS.PA
Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALCLS.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALCLS.PA
View MoreValuation Measures
Market Cap
134.19M
Enterprise Value
708.72k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.11
Price/Book (mrq)
1.31
Enterprise Value/Revenue
0.04
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-110.57%
Return on Assets (ttm)
-9.19%
Return on Equity (ttm)
-58.55%
Revenue (ttm)
54.75M
Net Income Avi to Common (ttm)
-60.53M
Diluted EPS (ttm)
-0.5900
Balance Sheet and Cash Flow
Total Cash (mrq)
127.64M
Total Debt/Equity (mrq)
92.92%
Levered Free Cash Flow (ttm)
-34.23M